JP2018528196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528196A5 JP2018528196A5 JP2018509622A JP2018509622A JP2018528196A5 JP 2018528196 A5 JP2018528196 A5 JP 2018528196A5 JP 2018509622 A JP2018509622 A JP 2018509622A JP 2018509622 A JP2018509622 A JP 2018509622A JP 2018528196 A5 JP2018528196 A5 JP 2018528196A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- disorder
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 206010052428 Wound Diseases 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims 2
- 208000002847 Surgical Wound Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000009043 Chemical Burns Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063562 Radiation skin injury Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206472P | 2015-08-18 | 2015-08-18 | |
| US62/206,472 | 2015-08-18 | ||
| PCT/US2016/047566 WO2017031323A1 (en) | 2015-08-18 | 2016-08-18 | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528196A JP2018528196A (ja) | 2018-09-27 |
| JP2018528196A5 true JP2018528196A5 (https=) | 2019-09-26 |
Family
ID=56799634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509622A Pending JP2018528196A (ja) | 2015-08-18 | 2016-08-18 | 癌の治療のための（ｓ，ｅ）−３−（６−アミノピリジン−３−イル）−ｎ−（（５−（４−（３−フルオロ−３−メチルピロリジン−１−カルボニル）フェニル）−７−（４−フルオロフェニル）ベンゾフラン−２−イル）メチル）アクリルアミド |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10363247B2 (https=) |
| EP (1) | EP3337797A1 (https=) |
| JP (1) | JP2018528196A (https=) |
| CN (1) | CN108137563A (https=) |
| AU (1) | AU2016308829A1 (https=) |
| CA (1) | CA2995380A1 (https=) |
| EA (1) | EA201890524A1 (https=) |
| HK (1) | HK1255438A1 (https=) |
| IL (1) | IL257422A (https=) |
| MA (1) | MA42655A (https=) |
| MX (1) | MX2018001979A (https=) |
| WO (1) | WO2017031323A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3016946B1 (en) | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| HK1255438A1 (zh) | 2015-08-18 | 2019-08-16 | 卡尔约药物治疗公司 | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| CN111171233B (zh) * | 2020-01-17 | 2023-03-31 | 吉林师范大学 | 一种新型磁性薄层印迹膜的制备方法及用途 |
| CN115569196B (zh) * | 2020-02-26 | 2024-06-18 | 上海科技大学 | 多酚类物质在抗冠状病毒中的应用 |
| CN114507215B (zh) * | 2020-11-14 | 2024-09-13 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19818044A1 (de) | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| ATE345341T1 (de) | 2001-07-19 | 2006-12-15 | Pfizer Italia Srl | Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| US7638540B2 (en) | 2003-05-29 | 2009-12-29 | The New Industry Research Organization | Benzofuran compound and medicinal composition containing the same |
| US7420066B2 (en) | 2003-08-07 | 2008-09-02 | Bayer Pharmaceuticals Corporation | Benzofuran derivatives useful for treating hyper-proliferative disorders |
| US7368476B2 (en) | 2004-04-07 | 2008-05-06 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| TW200616613A (en) | 2004-10-05 | 2006-06-01 | Shionogi & Co | Biaryl derivatives |
| JPWO2006054793A1 (ja) | 2004-11-19 | 2008-06-05 | 財団法人新産業創造研究機構 | ベンゾフラン化合物、およびそれを含有してなる医薬組成物 |
| JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用 |
| MX2007013065A (es) | 2005-04-22 | 2008-01-14 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| US20080020413A1 (en) | 2006-03-29 | 2008-01-24 | Columbia University | Crystalline visfatin and methods therefor |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| US8173677B2 (en) | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| CA2701071C (en) | 2007-09-26 | 2018-03-27 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| AU2011223790A1 (en) | 2010-03-01 | 2012-08-30 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| RU2017112522A (ru) | 2011-05-04 | 2019-01-24 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| CA2877474A1 (en) | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2014085607A1 (en) * | 2012-11-29 | 2014-06-05 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| EP3016946B1 (en) * | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) * | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| CA2921532A1 (en) | 2013-10-09 | 2015-04-16 | Eli Lilly And Company | Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors |
| US20170369470A1 (en) | 2014-12-16 | 2017-12-28 | Karyopharm Therapeutics Inc. | Cyclic Compounds and Uses Thereof |
| EP3337796A1 (en) | 2015-08-17 | 2018-06-27 | Karyopharm Therapeutics, Inc. | 3-(pyridin-3-yl)-acrylamide and n-(pyridin-3-yl)-acrylamide derivatives and their use as pak or nampt modulators |
| US20180244660A1 (en) | 2015-08-17 | 2018-08-30 | Karyopharm Therapeutics Inc. | Cyclopropylderivatives and their use as kinase inhibitors |
| HK1255438A1 (zh) | 2015-08-18 | 2019-08-16 | 卡尔约药物治疗公司 | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
| WO2017117406A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
-
2016
- 2016-08-18 HK HK18114602.1A patent/HK1255438A1/zh unknown
- 2016-08-18 US US15/753,897 patent/US10363247B2/en active Active
- 2016-08-18 MA MA042655A patent/MA42655A/fr unknown
- 2016-08-18 CA CA2995380A patent/CA2995380A1/en not_active Abandoned
- 2016-08-18 EA EA201890524A patent/EA201890524A1/ru unknown
- 2016-08-18 JP JP2018509622A patent/JP2018528196A/ja active Pending
- 2016-08-18 MX MX2018001979A patent/MX2018001979A/es unknown
- 2016-08-18 CN CN201680060621.6A patent/CN108137563A/zh active Pending
- 2016-08-18 AU AU2016308829A patent/AU2016308829A1/en not_active Abandoned
- 2016-08-18 EP EP16756931.8A patent/EP3337797A1/en not_active Withdrawn
- 2016-08-18 WO PCT/US2016/047566 patent/WO2017031323A1/en not_active Ceased
-
2018
- 2018-02-08 IL IL257422A patent/IL257422A/en unknown